Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 48,171 shares at $1.07 ($52K) on 2025-12-15, disclosed to the SEC on 2025-12-17.
Scheduled sale ($52k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.07 | 23,640 | $25K | 48.7% |
| 2 | $1.05 | 14,548 | $15K | 29.4% |
| 3 | $1.14 | 9,983 | $11K | 21.9% |
| Total | $1.08 avg | 48,171 | $52K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |